Tech Transfer Roundup: GE Healthcare, Vanderbilt Partner To Optimize Precision Cancer Immunotherapy
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
You may also be interested in...
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
The CE mark will make Hensify nanoparticle radioenhancers available in 27 European countries. Hensify is the brand name for NBTXR3, an aqueous suspension of crystalline hafnium oxide nanoparticles, approved specifically for treating locally advanced soft-tissue sarcoma.